Anti-androgen treatment for spinal and bulbar muscular atrophy

Editorial

Kenneth H Fischbeck et al. Ann Neurol. 2009 Feb.

. 2009 Feb;65(2):119-20.

doi: 10.1002/ana.21633.

No abstract available

Conflict of interest statement

Potential conflict of interest: Nothing to report.

Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.
Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, Takamori M, Ito M, Nakamura T, Matsuo K, Yamada S, Oki Y, Adachi H, Minamiyama M, Waza M, Atsuta N, Watanabe H, Fujimoto Y, Nakashima T, Tanaka F, Doyu M, Sobue G. Banno H, et al. Ann Neurol. 2009 Feb;65(2):140-50. doi: 10.1002/ana.21540. Ann Neurol. 2009. PMID: 19259967 Clinical Trial.

1. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77–79. - PubMed
1. Takeyama K, Ito S, Yamamoto A, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35:855–864. - PubMed
1. Katsuno M, Adachi H, Kume A, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35:843–854. - PubMed
1. Chevalier-Larsen ES, O’Brien CJ, Wang H, et al. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. J Neurosci. 2004;24:4778–4786. - PMC - PubMed
1. Katsuno M, Adachi H, Doyu M, et al. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med. 2003;9:768–773. - PubMed